INT93531

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2001
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 15
Total Number 15
Disease Relevance 7.74
Pain Relevance 2.84

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Tnfsf11) extracellular space (Tnfsf11) extracellular region (Tnfsf11)
plasma membrane (Tnfsf11) intracellular (Tnfsf11) cytoplasm (Tnfsf11)
Anatomy Link Frequency
joints 4
stromal cells 3
osteoblasts 3
PC-3 2
MC3T3-E1 2
Tnfsf11 (Mus musculus)
Pain Link Frequency Relevance Heat
Infliximab 2 99.98 Very High Very High Very High
dexamethasone 1 99.90 Very High Very High Very High
methotrexate 4 99.38 Very High Very High Very High
Arthritis 209 99.36 Very High Very High Very High
metalloproteinase 33 98.00 Very High Very High Very High
antagonist 29 96.28 Very High Very High Very High
rheumatoid arthritis 215 96.08 Very High Very High Very High
Inflammation 176 89.96 High High
cytokine 206 88.16 High High
Potency 1 68.96 Quite High
Disease Link Frequency Relevance Heat
Arthritis 245 99.36 Very High Very High Very High
Infection 11 98.16 Very High Very High Very High
Hypercalcemia 140 97.84 Very High Very High Very High
Atherosclerosis 38 97.12 Very High Very High Very High
Osteoporosis 97 96.72 Very High Very High Very High
Rheumatoid Arthritis 215 96.08 Very High Very High Very High
Multiple Myeloma 20 93.76 High High
Disease 69 93.36 High High
INFLAMMATION 181 89.96 High High
Calcification 118 87.56 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
U0126 (a MEK1/2 inhibitor) or LY294002 (a PI3K inhibitor) was added to ST2 and MC3T3-E1 cells, and was found to inhibit RANKL mRNA and RANKL protein expression in these cells.
Negative_regulation (inhibit) of Gene_expression (expression) of RANKL mRNA in MC3T3-E1
1) Confidence 0.43 Published 2007 Journal Mol. Cell. Biochem. Section Abstract Doc Link 17549607 Disease Relevance 0.41 Pain Relevance 0.04
Early studies demonstrated that co-culture of myeloma cells and BMSCs leads to marked induction of RANKL expression by both cell types, and a concomitant downregulation of OPG expression by BMSCs [5]; this illustrates the importance of interactions between myeloma cells and stromal cells.
Negative_regulation (downregulation) of Gene_expression (expression) of OPG in stromal cells
2) Confidence 0.41 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC1924519 Disease Relevance 0.59 Pain Relevance 0.16
It is, therefore, intriguing that THR0921 had the additional effect of reducing local expression of RANKL in affected joints.
Negative_regulation (reducing) of Gene_expression (expression) of RANKL in joints
3) Confidence 0.39 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1526548 Disease Relevance 0.33 Pain Relevance 0.17
OPG activity was detected in the culture medium from indomethacin-treated bones and PTH, PGE2, 1,25D3, and dexamethasone all inhibited the production of OPG activity.
Negative_regulation (inhibited) of Gene_expression (production) of OPG in PGE2 associated with dexamethasone
4) Confidence 0.35 Published 2001 Journal Bone Section Abstract Doc Link 11182380 Disease Relevance 0.21 Pain Relevance 0.11
evidences showed RANKL and OPG presence and activity in early and advanced
Negative_regulation (showed) of Gene_expression (presence) of OPG
5) Confidence 0.34 Published 2007 Journal Clinical and Developmental Immunology Section Body Doc Link PMC2248226 Disease Relevance 0.90 Pain Relevance 0.03
evidences showed RANKL and OPG presence and activity in early and advanced
Negative_regulation (showed) of Gene_expression (presence) of RANKL
6) Confidence 0.34 Published 2007 Journal Clinical and Developmental Immunology Section Body Doc Link PMC2248226 Disease Relevance 0.90 Pain Relevance 0.03
Excessive production of RANKL and/or a deficiency of OPG could, therefore, contribute to the increased bone resorption typified by the focal bone erosion and bone loss in RA.
Negative_regulation (deficiency) of Gene_expression (production) of RANKL associated with rheumatoid arthritis and hypercalcemia
7) Confidence 0.29 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1257432 Disease Relevance 0.85 Pain Relevance 0.36
VIP treatment of CIA mice resulted in a significant reduction in the expression of both RANK and RANKL, the mRNA levels of which in joints fell to near control values (non-CIA mice).
Negative_regulation (reduction) of Gene_expression (expression) of RANKL in joints associated with arthritis
8) Confidence 0.29 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1257432 Disease Relevance 0.95 Pain Relevance 0.44
Improving the RANKL/OPG ratio
Negative_regulation (Improving) of Gene_expression (ratio) of RANKL/OPG
9) Confidence 0.22 Published 2001 Journal Arthritis Res Section Body Doc Link PMC128900 Disease Relevance 0.79 Pain Relevance 0.47
The RANK–RANKL pathway is inhibited by a soluble competitor of RANKL, osteoprotegerin (OPG), which is secreted by the same cell population (osteoblasts and stromal cells) in response to different stimuli (estradiol, TGF-?
Negative_regulation (inhibited) of Gene_expression (pathway) of RANKL in osteoblasts
10) Confidence 0.20 Published 2008 Journal J Orthop Traumatol Section Body Doc Link PMC2657328 Disease Relevance 0.38 Pain Relevance 0.15
inhibits RANKL-induced human osteoclasto-genesis, it was paradoxical that IFN?
Negative_regulation (inhibits) of Gene_expression (osteoclasto) of RANKL-induced
11) Confidence 0.19 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592787 Disease Relevance 0.06 Pain Relevance 0.07
Mouse spleen cells and bone marrow macrophages express IL-4 and IL-13 receptors, and the addition of these factors decreased RANKL-stimulated tartrate-resistant acid phosphatase-positive multi-nucleated cell formation and cathepsin K message in spleno-cytes and bnone marrow macrophages [80].
Negative_regulation (decreased) of in macrophages Gene_expression (message) of RANKL-stimulated in bone marrow
12) Confidence 0.19 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2592787 Disease Relevance 0.59 Pain Relevance 0.26
Consistently with previous investigations in parental PC-3 cells [17], RANKL expression was undetectable in PC-3/Fluc, mock and Nog-KD clones.
Negative_regulation (undetectable) of Gene_expression (expression) of RANKL in PC-3
13) Confidence 0.11 Published 2011 Journal PLoS ONE Section Body Doc Link PMC3020964 Disease Relevance 0.11 Pain Relevance 0
It was shown that methotrexate, sulfasalazine and infliximab inhibit the expression of RANKL in RASFs in a dose-dependent manner, and increase the synthesis of osteoprotegerin, a RANKL antagonist, in RASF supernatants [25].
Negative_regulation (inhibit) of Gene_expression (expression) of RANKL associated with infliximab, antagonist and methotrexate
14) Confidence 0.07 Published 2007 Journal Arthritis Res Ther Section Body Doc Link PMC2246247 Disease Relevance 0.30 Pain Relevance 0.38
The RANK–RANKL pathway is inhibited by a soluble competitor of RANKL, osteoprotegerin (OPG), which is secreted by the same cell population (osteoblasts and stromal cells) in response to different stimuli (estradiol, TGF-?
Negative_regulation (inhibited) of in stromal cells Gene_expression (pathway) of RANKL in osteoblasts
15) Confidence 0.07 Published 2008 Journal J Orthop Traumatol Section Body Doc Link PMC2657328 Disease Relevance 0.38 Pain Relevance 0.15

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox